TGFB1 and myeloproliferative disorder: As inflammation is an integral characteristic of MPN pathophysiology and closely involved in disease progression, the efficacy of novel immunomodulatory drugs such as BET, BCL2, MDM2, and telomerase inhibitors as well as TGF-β superfamily ligands and interferons is currently being tested in a variety of clinical studies (Figure 2, Table 2).